---
title: "Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290455976.md"
description: "In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $5.24."
datetime: "2026-06-22T15:15:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290455976.md)
  - [en](https://longbridge.com/en/news/290455976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290455976.md)
generator: "portal-rs"
---

# Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $5.24.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T program](https://longbridge.com/en/news/297902766.md)
- [AcuCort notifies availability of August 2026 newsletter press release](https://longbridge.com/en/news/297505730.md)
- [Cogent Communications CFO Thaddeus Gerard Weed sells 4,850 shares for $45,445.99](https://longbridge.com/en/news/297927784.md)
- [J.P. Morgan Sticks to Its Buy Rating for AXA SA (0HAR)](https://longbridge.com/en/news/297996647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**